AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Nov 17, 2026, 4:05 PM ET PacBio will participate in a fireside chat at the Piper Sandler 38th Annual Healthcare Conference on December 2, 2026. AI-generated summary · Source: company release
Nasdaq: $PACBLife science tools · HiFi long-read sequencingRevenue flat, losses persistent$641.0M of notes due 2029 and 2030 against $199.4M of cash~17% of shares short

PACB Stock Hub: PacBio News, Long-Read Sequencing and the Debt Wall

Pacific Biosciences reported third-quarter 2026 revenue of $40.6 million on November 4, 2026, up 6% from a year earlier, with a GAAP gross margin of 33% and an operating loss of $37.0 million. Cash and investments fell to $199.4 million at September 30 while $641.0 million of convertible notes mature in August 2029 and December 2030. Those maturities are the residue of two exchanges, the second of which retired $459.0 million of 2028 notes for $200.0 million of new notes, 20.5 million shares and $50.0 million of cash. On November 10 the company added a $100 million at-the-market program; guidance is $155-160 million after two cuts.

Last updated: November 19, 2026Financials: quarter ended September 30, 2026Currency: U.S. dollars
Full research report · PDF
Pacific Biosciences (PACB) research report, as of November 19, 2026
17 pages: Scenarios, the two debt exchanges and the 2029 and 2030 notes, the third-quarter results, cash and burn, the platforms and the peer-reviewed evidence, dilution and the at-the-market program, ownership, legal matters, sources and FAQ. In the Merlintrader Research Library. A dated snapshot; this page follows the current situation. For personal use only: redistribution prohibited.
Get the report (PDF)
Next catalyst
First quarter of 2027 · $5.0 million PGI installment and the fourth-quarter report

The settlement with Personal Genomics of Taiwan requires $5.0 million in the first quarter of each of 2027, 2028 and 2029, with the 2027 payment rising by $1.0 million if 2026 revenue reaches $165.0 million and by another $1.0 million at $180.0 million; against guidance of $155-160 million, the base amount applies. The fourth-quarter and full-year 2026 results are expected in February 2027, as in recent years, and no date has been announced. Form 10-Q, September 30, 2026

Completed: on November 4, 2026 PacBio reported third-quarter revenue of $40,564,000, a net loss of $37.8 million, or $0.12 a share, and $199.4 million of cash and investments, and cut guidance to $155-160 million (results release). On November 3 Jim Gibson stepped down as Chief Financial Officer; Mark Van Oene, chief executive since August 5, took the finance role on an interim basis and Bill Meyer became Chief Accounting Officer (Form 8-K). On November 10 the company signed a sales agreement with Allen & Company for up to $100 million of stock sold at the market (Form 8-K).
Pacific Biosciences PACB daily stock chart
Daily chart $PACB. Source: Finviz, for information only. Interactive chart with bull and bear scenarios on JC Just Charts →

PACB stock at a glance

Chart analysis · JC
Technical chart analysis of $PACB with bull and bear scenarios on JC Just Charts.
Cash + investments · Sep 30
$199.4M
Against $279.5M at December 31, 2025 and $236.9M at June 30, 2026.
Revenue · September quarter
$40.6M
Up 6% from $38.4M; consumables $20.8M, instruments $13.2M, service and other $6.6M.
Gross margin · GAAP
33%
36% non-GAAP, against 42% a year earlier; memory costs and the Vega manufacturing transition.
Operating loss · September quarter
−$37.0M
Net loss $37.8M, or $0.12 a share; $90.0M of operating loss in nine months.
Convertible notes · face value
$641.0M
$200.0M of 1.50% notes due August 2029 and $441.0M of 1.375% notes due December 2030; $643.1M carrying value.
Short interest · Oct 30
17.2%
53,681,529 shares and 4.1 days to cover on Nasdaq figures, against 312,926,730 shares at October 31, 2026.

Where PacBio stands now

PacBio sells sequencing instruments and the consumables that run on them, built on single-molecule real-time (SMRT) sequencing and its high-fidelity (HiFi) read chemistry. Revio is the high-throughput instrument, running up to four SMRT Cells at once; Vega is the benchtop system. Both are sold for research use only. Third-quarter revenue was $40,564,000 — $20.8 million consumables, $13.2 million instruments, $6.6 million service — against $38,441,000 a year earlier; nine-month revenue was $116,749,000 against $115,360,000. Gross profit was $13.5 million at a 33% margin, the operating loss $37.0 million, and shares outstanding were 312,926,730 at October 31, 2026. Results release, November 4, 2026 · Form 10-Q

The mix moved the wrong way. Instrument revenue rose 16% on 15 Revio and 35 Vega placements against 13 and 32 a year earlier, but consumables — the recurring, higher-margin line — fell 2%, and annualized Revio pull-through came in at about $204,000 against about $236,000 a year earlier. Management cited memory costs and the Vega manufacturing transition. Source

Cash is the part that changed most: $199.4 million at September 30 against $279.5 million at December 31, 2025 and $236.9 million at June 30. Operations used $117.9 million in nine months, of which $37.6 million came in the third quarter alone (Merlintrader calculation: $117,879,000 less the $80,274,000 reported for six months). The company also collected $50.0 million gross from selling its short-read assets to Illumina Cambridge, netting about $48.1 million, and paid $8.0 million to Personal Genomics of Taiwan. Form 10-Q

The main risk: the debt outlives the cash. PacBio carries $641.0 million of convertible notes at face value — $200.0 million due August 15, 2029 and $441.0 million due December 15, 2030 — against $199.4 million of cash and investments. Neither series is near its conversion price, about $4.89 for 2029 and about $21.50 for 2030. At the third-quarter rate of $37.6 million the September balance covers about five quarters before any proceeds from the at-the-market program. The company says its cash funds operations beyond the next twelve months and discloses no substantial doubt about its ability to continue as a going concern; the open question is what happens between the end of that window and August 2029.

▲ The constructive case

HiFi is the most accurate long-read chemistry available, and the peer-reviewed record supports that: 99.8% read accuracy in Wenger et al., Nature Biotechnology 2019, and the best small-variant accuracy among long-read pipelines in the 2026 benchmark by Eveleigh et al., Genome Biology. SPRQ-Nx, launched on Revio in the second quarter and on Vega in August, cuts the list price of a human genome to $345 and already carries more than half of Revio consumables revenue, with two-thirds of the installed base upgraded to use it. Revenue is flat, gross margin has held above 30%, the July restructuring targets $30-40 million of annualized savings, and the balance sheet still holds $199.4 million.

▼ The cautious case

Two years of cost cutting have not restored growth: nine-month revenue rose 1%, consumables fell 2% in the quarter, and guidance has come down twice, from $165-175 million in May to $155-160 million in November. GAAP gross margin fell eight points on higher memory costs and Vega manufacturing transition costs. The quarter consumed $37.6 million of cash, and six weeks later the company registered a $100 million at-the-market program. Both the chief executive and the chief financial officer have left their roles since August, and $641.0 million of notes come due in 2029 and 2030.

Latest Pacific Biosciences news

Nov 17, 2026

PacBio to participate in the Piper Sandler 38th Annual Healthcare Conference

Management of PacBio will participate in a fireside chat at the Piper Sandler 38th Annual Healthcare Conference on Wednesday, December 2, 2026, in New York, New York. A live webcast will be available at investor.pacificbiosciences.com, with a replay available for at least 30 days following the event.

Nov 10, 2026

Pacific Biosciences files up to $100 million at-the-market stock offering

Pacific Biosciences filed a prospectus supplement dated November 10, 2026, for an at-the-market offering of up to $100,000,000 of common stock. Allen & Company LLC acts as sales agent and receives an amount up to 3% of the gross proceeds of any shares sold. The offering is made under an automatic shelf registration filed February 25, 2026. The last reported sale price on Nasdaq was $2.36 per share on November 9, 2026.

Nov 5, 2026

Barclays lifts Pacific Biosciences price target to $2 from $1.25, Underweight kept

Barclays raised its price target on Pacific Biosciences to $2 from $1.25. The bank kept its Underweight rating on the stock. Analyst action reported by the press; it is the bank's view, not Merlintrader's.

Nov 5, 2026

Piper Sandler lifts Pacific Biosciences price target to $3

Piper Sandler raised its price target on Pacific Biosciences to $3 from $2. Analyst action reported by the press; it is the bank's view, not Merlintrader's.

Nov 4, 2026

PacBio announces third quarter 2026 financial results

PacBio reported revenue of $40.6 million for the quarter ended September 30, 2026, compared with $38.4 million a year earlier. GAAP net loss was $37.8 million, or $0.12 per share, versus $38.0 million, or $0.13 per share, in the third quarter of 2025. PacBio now expects full-year 2026 revenue in the range of $155 million to $160 million. Jim Gibson stepped down as Chief Financial Officer, and Mark Van Oene was appointed interim CFO.

Nov 3, 2026

Pacific Biosciences begins rollout of SPRQ-Nx chemistry for HiFi sequencing

Pacific Biosciences of California has initiated the rollout of its SPRQ-Nx chemistry. The rollout extends the reach of its HiFi sequencing. Not confirmed by a company release or filing at the time of writing; to be verified.

PACB stock catalysts: the dated calendar

  • January 30, 2026 — Sale of the short-read assets to Illumina Cambridge for $50.0 million in cash plus assumed liabilities; net proceeds of about $48.1 million and a $45.8 million gain. Completed · Form 8-K
  • March 5, 2026 — Term sheet with Personal Genomics of Taiwan: royalty-free license, covenant not to sue, dismissal of all claims, $8.0 million paid in 2026 and $5.0 million in the first quarter of 2027, 2028 and 2029. Completed · Form 8-K
  • July 30, 2026 — Restructuring: about 40 positions, roughly 8% of the workforce, with $30-40 million of annualized savings targeted by the end of 2027. Completed · Form 8-K
  • August 5, 2026 — Mark Van Oene becomes President and Chief Executive Officer, succeeding Christian Henry, who remains on the board and as Senior Business Advisor until December 31, 2026. Completed · Form 8-K
  • November 3, 2026 — Jim Gibson steps down as Chief Financial Officer; Van Oene becomes interim CFO and Bill Meyer Chief Accounting Officer. Completed · Form 8-K
  • November 4, 2026 — Third-quarter results: revenue $40.6 million, net loss $0.12 a share, cash $199.4 million, guidance cut to $155-160 million. Completed · company release
  • November 10, 2026 — Sales agreement with Allen & Company for up to $100 million of stock at the market, commission up to 3.0%. Completed · Form 8-K
  • First quarter of 2027 — $5.0 million PGI installment due, plus $1.0 million for each 2026 revenue threshold met. Contractual
  • February 2027 — Fourth-quarter and full-year 2026 results, the first report against the $155-160 million range. Expected; no date announced
  • August 20, 2027 — The 2029 notes become redeemable at the company’s option if the shares have traded at 150% of the conversion price. Contractual
  • August 15, 2029 — $200.0 million of 1.50% convertible notes mature. Contractual
  • December 15, 2030 — $441.0 million of 1.375% convertible notes mature. Contractual

The Revio and Vega platform

HIGH THROUGHPUT

Revio

Revio runs up to four SMRT Cells at once and is the instrument the consumables business depends on. PacBio placed 15 units in the third quarter, 20 in the second and 15 in the first, against 13 a year earlier and 61 for all of 2025. Annualized pull-through was about $204,000 per system, down from about $236,000, as SPRQ-Nx lowered the price of a genome; more than half of Revio consumables revenue came from the new chemistry. Source

BENCHTOP

Vega

Vega runs a single SMRT Cell and is the entry point for smaller laboratories. PacBio placed 35 units in the third quarter, up 9% from 32 a year earlier, and more than 90% went to first-time customers; placements were 27 in the first quarter and 26 in the second, against 140 for all of 2025. Vega carried the transition costs that depressed gross margin. Source

CHEMISTRY AND KITS

SPRQ-Nx, Kinnex, PureTarget

SPRQ-Nx is the cost-reduction chemistry: PacBio put the list price of a human genome at $345 when the global rollout began in the second quarter of 2026, with methylation detection and DeepConsensus, a consensus algorithm developed with Google. Kinnex kits convert short amplicons into long fragments for RNA work and PureTarget panels target repeat expansions. Source

The convertible notes in one table

Item2029 notes2030 notes
Principal outstanding$200.0 million$441.0 million
Coupon1.50%, paid February 15 and August 151.375%, paid June 15 and December 15
MaturityAugust 15, 2029December 15, 2030
Conversion priceAbout $4.89 a share (204.5157 shares per $1,000)About $21.50 a share (46.5116 shares per $1,000)
OriginNovember 2024 exchange with SB Northstar LP, a SoftBank subsidiary, for $459.0 million of 1.50% notes due 2028, plus 20,451,570 shares and $50.0 million of cashJune 2023 exchange with a holder of the 2028 notes, for $441.0 million of that series
Carrying value · Sep 30, 2026$209.0 million, of which $206.0 million is debt and $3.0 million sits in accrued expenses$437.1 million, net of $4.3 million of unamortized issuance costs
Fair value · Sep 30, 2026$197.4 million$334.6 million

The two series are the whole of PacBio’s funded debt: $641.0 million of principal and $9.1 million of annual cash interest (Merlintrader calculation) against $199.4 million of cash and negative operating cash flow. The 2029 notes carry a letter agreement with SB Northstar that restricts additional debt and liens while the holder owns at least $180.0 million of principal, with an exception for up to $75.0 million of secured borrowing. Form 10-Q, Note 4

Pacific Biosciences deep dive: the full analysis

The scenarios, the technology and the clinical evidence, the two debt exchanges and the notes they left behind, the third-quarter 2026 results and the cost reset, cash and burn, dilution and the at-the-market program, ownership and short interest, legal and competitive risk. The Merlintrader Research Library collects our dated biotech stock research reports.

01 Three scenarios: demand, cost and the 2029 wall

Bull case — SPRQ-Nx turns a price cut into volume

The favorable case does not require PacBio to win the sequencing market. It requires the company to show that a lower price per genome expands its own demand faster than it erodes revenue per sample. SPRQ-Nx carried more than half of Revio consumables revenue, and two-thirds of the installed base were opting to upgrade software to run it by September 30, 2026. Revenue per system fell, though: annualized Revio pull-through was about $204,000 against about $236,000 a year earlier. Source

The second leg is clinical. HiFi is the platform behind most of the published evidence on long-read rare disease diagnostics, from the 100-sample study by Höps et al., American Journal of Human Genetics 2025, to the 1,000-sample series by de Bitter et al., New England Journal of Medicine 2026. If laboratories consolidate exome, genome, repeat-expansion and methylation testing onto one instrument, the consumables pool grows without a single new placement. Revenue of $175-190 million in 2027 at a 38-40% gross margin, against a cost base reduced by $30-40 million, would leave a company burning $70-80 million a year and able to refinance 2029. Every figure here is a Merlintrader scenario. Source

Base case — flat revenue, smaller losses, a financing every eighteen months

The middle case starts from what the company has delivered. Revenue was $116.7 million in nine months, up 1%, and guidance of $155-160 million implies $38.3-43.3 million in the fourth quarter (Merlintrader calculation). GAAP gross margin has run at 32-35% and non-GAAP gross margin at 36-37% over the past three quarters. Annualized non-GAAP operating expense was about $188 million in the September quarter ($46.95 million times four), and the restructuring is meant to remove $30-40 million of that by the end of 2027. At $160 million of revenue and a 36% margin, gross profit is about $57.6 million against roughly $188 million of expense — an operating loss near $130 million before savings. Even after $40 million of cuts, break-even at 36% would need about $410 million of revenue. Source

That arithmetic explains the financing pattern. In the base case PacBio grows in the low single digits through 2027, keeps gross margin in the mid-30s and funds a $100-130 million annual cash deficit with the at-the-market program and whatever else the market will buy. Cash of $199.4 million covers about five quarters at the third-quarter rate, so the program signed on November 10 buys roughly three more. Source

Bear case — the cost base outlives the demand

The adverse case is not a technology failure. Instrument demand depends on academic and government budgets outside PacBio’s control. If revenue stays near $155 million and gross margin slips to 30%, gross profit falls to about $47 million against a cost base that comes down slowly. Source

The equity is then squeezed three ways. Cash consumption of $150 million a year exhausts the September balance in early 2028 unless the at-the-market program is used heavily, and heavy use at low prices transfers value to new buyers. The 2029 notes cannot be repaid from cash and cannot convert at $4.89, so a second exchange would be needed on worse terms than the 2024 one, which already cost 20.5 million shares and $50 million of cash for $259 million of principal reduction. None of this requires the technology to stop working; it requires the market to grow more slowly than the cost base.

02 What would falsify this reading

The reading is that PacBio owns a differentiated technology, sells it into a market growing slowly, and carries a debt structure that makes the next financing as important as the next product.

  • Consumables per system stop falling while total consumables grow. The clearest evidence of a working price cut is Revio pull-through stabilizing above $200,000 while the installed base expands. Consumables fell 2% in the September quarter even as instrument revenue rose 16%; a second quarter of that pattern would say SPRQ-Nx is cutting price without buying volume. Source
  • Gross margin recovers toward 40%. Non-GAAP gross margin fell from 42% to 36% on higher memory costs and Vega manufacturing transition costs. If those costs prove temporary, margin should recover; a margin still in the mid-30s at the end of 2027 would mean the cost structure has reset permanently lower. Source
  • A financing that is not dribbled out through the at-the-market program. A negotiated raise or an exchange that pushes maturities past 2030 would improve the case; accelerating sales under the $100 million program, or a second exchange paid in shares, would confirm the dilution path. Source
  • Clinical reimbursement rather than clinical publications. The literature already models long-read sequencing as a first-tier test with a modest gain in diagnostic yield. What would change revenue is payment: coverage decisions, laboratory-developed test economics at scale, or a guideline naming long-read genome sequencing as standard for undiagnosed rare disease. de Bitter et al., New England Journal of Medicine 2026
  • Another guidance cut, or another finance departure. Guidance has gone from $165-175 million to $155-165 million to $155-160 million in six months, and the Chief Financial Officer left in November. A third cut, a delay in hiring a permanent finance chief, or an impairment of goodwill would each weaken the execution case. Source

03 What PacBio sells, and to whom

Pacific Biosciences of California, Inc. was incorporated in Delaware in 2000 and is based in Menlo Park, California. It designs, manufactures and sells instruments, consumables and service around SMRT sequencing, in which a polymerase synthesizes DNA inside a zero-mode waveguide and a camera reads the fluorescent signal of each incorporated base. The commercial product is the HiFi read: a consensus sequence built by reading the same circular template many times, trading throughput for accuracy. Form 10-K for 2025

Customers are institutional: academic and government institutions, commercial testing laboratories, genome centers, public health laboratories, hospitals and clinical research institutes, contract research organizations, pharmaceutical and agricultural companies. In the first nine months of 2026 instruments produced $35.7 million, consumables $62.7 million and service $18.3 million; by geography the Americas produced $52.5 million, Europe, the Middle East and Africa $39.2 million and Asia-Pacific $25.0 million, with EMEA up 33% and Asia-Pacific down 26%. Form 10-Q

The business changed shape in 2025 and 2026. After buying Omniome in 2021 PacBio ran short-read and long-read platforms in parallel; the 2025 restructuring abandoned that strategy, with $382.4 million of charges in the first nine months of 2025, of which $359.3 million of accelerated amortization, $15.0 million of impairment and $4.8 million of severance, and on January 30, 2026 it sold the short-read intellectual property to Illumina Cambridge for $50.0 million in cash plus assumed liabilities, booking a $45.8 million gain and netting about $48.1 million after paying 4% of the proceeds to former Apton holders. Form 8-K, February 2, 2026

Manufacturing is concentrated in Menlo Park, which holds ISO 13485 and ISO 9001 certifications; some components are sole-sourced. A supply agreement with a semiconductor manufacturer carries minimum purchases through 2031 in exchange for guaranteed capacity, with $8.0 million of deposits in other long-term assets at December 31, 2025. The company had 485 full-time employees at that date, before the 40-position reduction of July 2026. Backlog was $49.2 million, down from $58.6 million, of which about 80% was expected to convert in 2026; the total backlog is roughly a third of a year’s revenue, so the business runs mostly on orders taken and shipped within the quarter. Form 10-K for 2025

04 The technology case against the literature

HiFi accuracy is one of the better-documented results in genomics. Wenger et al., Nature Biotechnology 2019, optimized circular consensus sequencing and reported reads of 99.8% accuracy averaging 13.5 kilobases, single-nucleotide variant precision and recall of at least 99.91%, structural variant precision and recall of 95.99%, and 99.64% of variants phased into haplotypes; a de novo assembly from those reads alone reached a contig N50 above 15 megabases. Several of the paper’s authors worked at Pacific Biosciences. Wenger et al., Nature Biotechnology 2019

Independent benchmarks agree on the direction. Eveleigh et al., Genome Biology 2026, compared short-read, synthetic long-read and long-read platforms and found PacBio Revio with DeepVariant produced the highest single-nucleotide and indel accuracy genome-wide among long-read pipelines, while long-read callers dominated structural variant detection; long reads saturated at 20-45x coverage where short reads needed more than 60x. Küçük et al., Genome Medicine 2023, whose authors include Pacific Biosciences employees, sequenced eight parent-child trios with both technologies and called 24 de novo structural variants with HiFi against one with short reads, of which 10 of the 19 HiFi-only candidates that could be tested were confirmed as true de novo events, and phased 96% of de novo mutations to the correct parent against 20%. Eveleigh et al., Genome Biology 2026 · Küçük et al., Genome Medicine 2023

Assembly is the second pillar. Nurk et al., Science 2022, published the telomere-to-telomere CHM13 reference, a 3.055 billion base-pair sequence that closed the last 8% of the genome and added nearly 200 million base pairs of previously unresolved sequence. Rautiainen et al., Nature Biotechnology 2023, automated the method in Verkko, which builds a diploid assembly from accurate long reads plus ultra-long reads and produced 20 of 46 chromosomes gapless at 99.9997% accuracy on the HG002 cell line. HiFi reads are the accurate backbone in both, with ultra-long nanopore reads supplying reach across the largest repeats. Nurk et al., Science 2022 · Rautiainen et al., Nature Biotechnology 2023

The third pillar is methylation, which the company monetizes most directly. Circular consensus reads native DNA, so polymerase kinetics carry information about methylated bases without bisulfite conversion. Ni et al., Nature Communications 2023, built a deep-learning caller for 5-methylcytosine from PacBio reads and reached 0.90 accuracy and 0.97 area under the curve at single-molecule resolution, with genome-wide correlations above 0.90 against bisulfite and nanopore sequencing at 10x coverage. Whether methylation signatures can classify variants of uncertain significance is a separate clinical question that this paper does not test. Ni et al., Nature Communications 2023

What the literature does not show is that accuracy wins the market. Oxford Nanopore Technologies offers long reads with a different trade-off — lower raw accuracy, longer reads, a cheaper instrument — and competes for the same structural variant and methylation work; the 2026 benchmark found nanopore R10 strong in clinically relevant loci and PacBio stronger genome-wide. Eveleigh et al., Genome Biology 2026

05 Clinical adoption and the evidence

Rare disease is where long-read sequencing has the clearest clinical argument, and the evidence has moved from case reports to cohorts. Höps et al., American Journal of Human Genetics 2025, took 100 samples carrying 145 known pathogenic variants that are hard to detect with short reads — structural variants, variants in homologous sequences, repeat expansions — and found that standard callers re-identified 83% automatically, another 10% were visible on inspection, and 93% were identified in total. A titration analysis found 90% of the automatically called variants still detectable at 15-fold coverage. Several of the authors were affiliated with Pacific Biosciences. Höps et al., American Journal of Human Genetics 2025

Del Gobbo and Boycott, Genome Research 2025, reviewed more than 50 studies and concluded that long-read sequencing adds 7-17% diagnostic yield after a negative short-read genome, mainly through structural variants, repeat expansions and phasing. Ek et al., Genome Medicine 2026, compared short-read sequencing with Oxford Nanopore long reads in 100 children and found the same 29% diagnostic yield with both, with long reads adding resolution rather than diagnoses. Del Gobbo and Boycott, Genome Research 2025

The largest clinical series is more sobering and more useful. De Bitter et al., New England Journal of Medicine 2026, ran long-read genome sequencing at about 30-fold coverage on 1,000 clinical samples from two tertiary centers and compared it with standard-of-care testing. Concordance was 96.4%. Long reads improved or refined a diagnosis in 3.4% of cases, largely through phasing for recessive disorders, while standard testing found variants long reads missed in 0.2% of cases; modeling long reads as a first-tier test across 15,150 index cases produced an estimated absolute gain in yield of 2.5%. de Bitter et al., New England Journal of Medicine 2026 · Ek et al., Genome Medicine 2026

PacBio’s commercial strategy follows that logic: sell the consolidation, not the extra diagnosis. The economic obstacle remains price. Küçük et al. noted that long-read sequencing was still three to six times more expensive than short-read sequencing depending on platform and local infrastructure, which is exactly the gap SPRQ-Nx is meant to close; PacBio put the list price of a HiFi human genome at $345 in the second quarter of 2026. Source · Küçük et al., Genome Medicine 2023

06 The debt exchange of November 2024

The November 2024 debt exchange is a completed transaction whose consequences run to the end of the decade. On November 7, 2024 PacBio signed an exchange agreement with SB Northstar LP, a subsidiary of SoftBank Group Corp., to swap the remaining $459.0 million of its 1.50% convertible senior notes due 2028 for three things: $200.0 million of new 1.50% convertible senior notes due 2029, 20,451,570 shares of common stock and $50.0 million of cash. The shares were issued and the exchange closed on November 21, 2024. PacBio received no cash proceeds; it paid $50.0 million and issued stock to retire $459.0 million of principal. Form 10-Q, Note 4

The accounting shows how distressed the starting point was. PacBio treated the exchange as a troubled debt restructuring under ASC 470-60, the guidance for debtors in financial difficulty. Because the undiscounted cash flows of the new notes were lower than the carrying amount of the old ones, it recorded the new notes at the total of those cash flows and recognized a $154.4 million gain in 2024, equal to a $0.56 reduction in basic net loss per share. Form 10-K, 2025

The terms are ordinary for a convertible, severe at this scale. The 2029 notes pay 1.50% semi-annually, mature on August 15, 2029 and convert at 204.5157 shares per $1,000, or about $4.89 a share; PacBio may settle in cash, shares or a combination. They become redeemable at the company’s option from August 20, 2027. On a fundamental change, holders can require repayment at par plus accrued interest and all unpaid interest to maturity — a repurchase price that includes future coupons. Form 10-Q

The price was dilution and a covenant. The 20,451,570 shares handed over in a single day were about the size of nine months of equity grants at the 2026 rate, and they came on top of $50.0 million of cash. In exchange PacBio removed $259.0 million of principal from a maturity then more than three years away and replaced it with $200.0 million due in 2029: a real deleveraging. The question is not whether the 2024 exchange was a good deal — with $459 million due in 2028 and no cash generation, it was close to unavoidable — but whether the exercise will be available in 2028 on better terms. The fair value of the 2029 notes at September 30, 2026, $197.4 million against $200.0 million of principal, says the market expects repayment. Form 10-Q

The Letter Agreement signed with SB Northstar the same day constrains strategy. While SB Northstar and its affiliates hold at least $180.0 million of principal, PacBio may not incur additional indebtedness or create liens, subject to exceptions including up to $75.0 million of secured borrowing, and may not guarantee other debt or incur certain debt outside the ordinary course unless it concurrently guarantees the 2029 notes. SB Northstar also cannot be issued shares taking its beneficial ownership above 9.9%. Form 10-Q, Note 4

07 The 2030 notes and the maturity wall

The larger block of debt came earlier and more quietly. In June 2023 PacBio signed a privately negotiated exchange with a holder of its 2028 notes and issued $441.0 million of new 1.375% convertible senior notes due 2030 for the same principal amount of 2028 notes; no cash changed hands. The 2030 notes pay interest on June 15 and December 15, mature on December 15, 2030 and convert at 46.5116 shares per $1,000, or about $21.50 a share. Issuance costs of $7.3 million are amortized at an effective rate of 1.6%; the net carrying amount was $437.1 million at September 30, 2026 and interest expense was $5.3 million in nine months. Form 10-Q, Note 4

Between the two series PacBio owes $641.0 million of principal, $200.0 million in August 2029 and $441.0 million in December 2030. The conversion prices make the equity option theoretical: about $21.50 for the 2030 notes and about $4.89 for the 2029 notes, neither close to the level at which the shares have been changing hands. Neither converts in the ordinary course unless the equity re-rates by a multiple, so both should be treated as cash obligations. Their combined fair value at September 30 was $532.0 million, about 83 cents on the dollar of principal (Merlintrader calculation: $197.4 million plus $334.6 million against $641.0 million), a discount reflecting time value, the 1.4-1.5% coupons and credit risk. Form 10-Q

Both indentures carry the standard package: events of default that can accelerate the notes, a holder right to require repurchase on a fundamental change, and a reporting covenant whose breach triggers additional interest of 0.25% a year for 180 days and 0.50% for the next 180. In practice the company has $641.0 million of debt it cannot convert, $199.4 million of cash, negative operating cash flow and a covenant that restricts new borrowing. Form 10-Q

The company’s own risk factor states the position without euphemism: “We are not cash flow positive and may not have sufficient cash to make required payments under the terms of our debt or fund our long-term planned operations.” The liquidity discussion says existing cash will fund projected requirements beyond the next twelve months from the filing date — a twelve-month statement about debt that matures in three and four years. A company in that position has four ways out: grow into the debt, refinance it, exchange it for equity again, or sell the business. Form 10-Q

08 Revenue, margin and the cost reset

Third-quarter revenue was $40,564,000, up 6% from $38,441,000, and the mix moved against the company. Instrument revenue rose 16% to $13.2 million on 15 Revio and 35 Vega placements, service rose 12% to $6.6 million, and consumables — the higher-margin, recurring line — fell 2% to $20.8 million. Nine-month revenue was $116,749,000 against $115,360,000, with consumables up 4% to $62.7 million, instruments down 2% to $35.7 million and service down 2% to $18.3 million. Form 10-Q

Gross margin compressed by eight points. GAAP gross profit was $13.5 million, or 33% of revenue, against $15.9 million and 41% a year earlier; non-GAAP margin was 36% against 42%. Management attributed the decline in non-GAAP gross margin to higher memory costs and Vega manufacturing transition costs. Results release

Operating expenses came down. GAAP operating expense was $50.5 million against $54.8 million, with research and development at $20.2 million and selling, general and administrative at $29.4 million; non-GAAP was $47.0 million against $53.9 million. Share-based compensation was $8.5 million in the quarter and $22.3 million in nine months. Form 10-Q

The cost reset has run for two years. The 2025 restructuring produced $382.4 million of charges in the first nine months of 2025, mostly accelerated amortization, plus a $15.0 million impairment and $4.8 million of severance. The July 30, 2026 plan removed about 40 positions, roughly 8% of a workforce that numbered 485 at the end of 2025, at a cost of $1.8 million, and targets $30-40 million of annualized savings by the end of 2027; the filing says it expects more than $30 million against the level before the restructuring. Form 8-K, August 5, 2026

Guidance has moved in one direction: $165-175 million in May, $155-165 million in August, $155-160 million in November. The current range implies fourth-quarter revenue of $38.3-43.3 million (Merlintrader calculation) against $44.6 million a year earlier, which would leave 2026 flat to slightly below the $160.0 million reported for 2025. Fourth-quarter 2025 release

The arithmetic of the cost base gets least attention. Annualized non-GAAP operating expense of about $188 million against a 36% gross margin requires roughly $410 million of revenue to break even after $40 million of savings, and about $522 million before them (Merlintrader calculation). Revenue was $200.5 million in 2023, before the short-read exit; it has not been above $160 million since. Cost cuts of $30-40 million are meaningful against a $130 million operating loss but do not close a gap of that size; only growth or a much higher margin does. Source

09 Cash, burn and runway

Cash, cash equivalents and investments were $199,418,000 at September 30, 2026 against $279,506,000 at December 31, 2025, a 29% decline in nine months. Operations used $117,879,000, against $92,140,000 a year earlier. Investing provided $107,041,000, mostly from $132.7 million of maturities and the $50.0 million Illumina proceeds, offset by $61.2 million of new purchases, $5.6 million of property and equipment and $5.0 million of intangibles. Financing provided $3,148,000, essentially employee stock plans, and the net change in cash including restricted cash was a decline of $7,690,000. Form 10-Q

The quarterly pattern matters more than the nine-month total. Operating cash use was $80,274,000 in the six months to June 30, which leaves $37,605,000 for the third quarter alone (Merlintrader calculation). That is $13.1 million a month across nine months and $12.5 million in the third quarter, below the $14.9 million a month of the first quarter and close to the second quarter’s $11.9 million. Form 10-Q, June 30, 2026 · Form 10-Q, March 31, 2026

Dividing the September balance by the third-quarter rate gives about five quarters of coverage, into early 2028; adding the full $100 million at-the-market program extends it to about eight quarters, into late 2028, before commissions of up to 3.0% (Merlintrader calculations). Neither figure accounts for $9.1 million of annual cash interest, the $5.0 million PGI installments in the first quarter of 2027, 2028 and 2029, or a widening operating loss. Form 8-K, November 10, 2026

Working capital is absorbing cash rather than releasing it. Inventory rose to $60.3 million from $49.3 million, a 22% increase while revenue was flat, and receivables were $38.3 million against $35.4 million. Deferred revenue of $21.6 million is a partial offset. Form 10-Q

The runway calculation has one caveat: historical burn is a poor guide to a company cutting costs and launching a cheaper chemistry at the same time. If the $30-40 million of savings arrive and margin recovers, the quarterly burn falls. Until shares are sold, the runway is the $199.4 million. Prospectus supplement

10 Dilution and the at-the-market program

The share count grows every year. PacBio had 301,998,292 shares outstanding at January 31, 2026, 310,487,099 at the April 6 record date for its annual meeting and 312,926,730 at October 31. The 8.5 million shares added in the first quarter came mostly from vesting restricted stock units granted in earlier years and from the employee stock purchase plan, which issued 2,375,988 shares in nine months. Form 10-K for 2025

The larger overhang is contractual. Options outstanding were 22,451,000 at September 30, 2026 with a weighted average exercise price of $4.56, after 9,762,000 granted in nine months at a weighted average of $1.56; restricted stock units were 17,325,000 after 10,721,000 granted. With performance awards, 42,287,000 shares were excluded from diluted earnings per share as antidilutive, and another 61,415,000 are issuable on conversion of the notes. The fully diluted count is about 416 million shares against 313 million outstanding, a potential increase of roughly 33% (Merlintrader calculation). Form 10-Q

The at-the-market program is the newest source. Under the sales agreement signed on November 10, 2026, PacBio may sell up to $100,000,000 of common stock through Allen & Company, in negotiated transactions or by any method permitted as an at-the-market offering, with commission of up to 3.0%. What it costs depends on the price at which it is used: at a dollar a share, every $50 million raised would add 50 million shares, about 16% of the current count (Merlintrader illustration). Form 8-K

11 Ownership, short interest, insiders

The institutional register has rotated rather than grown. ARK Investment Management and Catherine D. Wood reported 37,264,228 shares, 12.34% of the class, at December 31, 2025 and 29,781,416 shares, 9.59%, at June 30, 2026 — a reduction of about 7.5 million shares in six months. The Vanguard Group filed an amendment reporting zero shares at March 13, 2026 after an internal realignment in January. T. Rowe Price Associates reported 33,445,993 shares, 10.8%, at October 31, 2026, and The Goldman Sachs Group with Goldman Sachs & Co. reported 23,515,935 shares, 7.6%, at September 30, 2026. 13G/A, The Vanguard Group, March 27, 2026 · 13G/A, February 3, 2026 · 13G/A, August 14, 2026 · 13G, November 6, 2026 · 13G, November 9, 2026

Short interest is high. Nasdaq reported 53,681,529 shares short at the October 30, 2026 settlement date, 17.2% of the 312,926,730 shares outstanding at October 31 (Merlintrader calculation) and 4.1 days to cover on average daily volume of 12,977,933 shares. The position was 46,933,159 shares at October 15 and 47,224,448 at September 30, so the last two weeks of October added about 6.7 million shares. Nasdaq short-interest table, October 30, 2026

Insider sales in 2026 were mostly tax-related, and the transaction codes matter. No Form 4 filed in 2026 reports an open-market purchase. Christian Henry, then chief executive, sold 331,793 shares on February 17 and 140,874 on February 18, and 12,497 on March 3; Mark Van Oene, then chief operating officer and now chief executive, sold 129,790 and 55,107 on the same February dates, 6,504 on March 3 and 26,911 on August 17 after restricted stock vested; Michele Farmer, then chief accounting officer, sold 35,215 and 14,952 in February and 2,979 in March. Each of these Form 4 filings is coded S and describes the shares as sold to cover tax withholding on vesting restricted stock units. Jim Gibson’s October filing is the one to read carefully: on October 6, while still chief financial officer, he exercised 500,000 options at $1.18 and sold 661,815 shares under a plan adopted on May 22, 2026, including 161,815 from vested units. The exercise is code M, which is not a purchase with new money, and the sale is code S; his direct holding after the transactions was 1,083,848 shares. Form 4, February 19, 2026 · Form 4, October 8, 2026

12 Competition, legal matters, risks

PacBio competes with companies that are larger, better funded or both. Its 2025 annual report names Illumina, BGI Genomics, Thermo Fisher Scientific, Oxford Nanopore Technologies, Roche, Qiagen, Element Biosciences, Bionano Genomics, Ultima Genomics and 10x Genomics. Form 10-K for 2025

The main legal matter was settled in 2026. Personal Genomics of Taiwan sued PacBio in 2019 in the District of Delaware for infringement of U.S. Patent No. 7,767,441; on March 5, 2026 the parties signed a term sheet: a worldwide royalty-free non-exclusive license, a five-and-a-half-year covenant not to sue, dismissal of all claims, $8.0 million paid in 2026 and $5.0 million in the first quarter of each of 2027, 2028 and 2029, with the 2027 payment rising by $1.0 million at $165.0 million of 2026 revenue and another $1.0 million at $180.0 million. PacBio recorded $15.4 million of settlement charges in the first quarter. Form 8-K, March 6, 2026

No securities class action is pending: the annual report mentions only past litigation of that kind, and the September 30 quarterly report lists no proceeding beyond the settled PGI matter. Form 10-Q

One balance-sheet item matters more than the rest. Goodwill was $317,761,000 at September 30, 2026, unchanged all year and equal to 44% of total assets, against stockholders’ equity of negative $61,380,000: a company with negative book equity and a goodwill balance that large is one downward revision to its long-range forecast away from a non-cash impairment charge. The asset base that supports the equity is mostly goodwill and expectation. Form 10-Q

The operating risks are ordinary for an instrument company: sole-sourced components, a semiconductor agreement with minimum purchases through 2031, tariffs and export controls that affect costs and sales into China, and academic and government funding in the United States that determines whether the instrument funnel fills. Form 10-Q

The risk that matters most is the one the company cannot cut its way out of. PacBio has taken $382.4 million of restructuring charges and cut staff in successive rounds, and on the third-quarter run-rate still loses about $148 million a year on an operating basis. It has not shown that it can sell enough genomes at $345 each to cover a $188 million cost base. Until it does, the equity is a call option on that demonstration, financed by shares sold into the market and by debt that matures in 2029 and 2030. Source

Merlintrader Health Score · $PACB

2.05out of 5
Balance sheet and runway · 30%1.5

$199.4 million of cash at September 30, 2026 against $641.0 million of notes at face value, $200.0 million due in August 2029 and $441.0 million in December 2030. Operations used $37.6 million in the quarter; the $100 million at-the-market program extends coverage from about five quarters to about eight.

Catalyst · 30%2.5

Revenue grew 6% and SPRQ-Nx carries more than half of Revio consumables revenue, but guidance was cut twice and the fourth quarter implies $38.3-43.3 million against $44.6 million a year earlier. The next dated test is the fourth-quarter report expected in February 2027.

Dilution · 20%1.5

312,926,730 shares at October 31, up 3.6% since January; 42.3 million shares in equity awards, 61.4 million issuable on the notes, 40.8 million still available under the plans and a $100 million at-the-market program on top.

Liquidity · 10%3.5

Active Nasdaq Global Select trading; 53,681,529 shares short at October 30, 2026, 17.2% of the count and 4.1 days to cover. No bid-price notice or listing deficiency disclosed.

Execution · 10%2.0

GAAP gross margin of 33% against 41%, consumables down 2% and two guidance cuts in six months. The July restructuring removed about 40 positions on schedule and targets $30-40 million of savings; in the same period the chief executive changed on August 5 and the chief financial officer on November 3.

Assessed on November 19, 2026, after the third-quarter results, the September 30, 2026 financial statements, the November 3 finance transition and the November 10 at-the-market program. Weighted calculation: 1.5×30% + 2.5×30% + 1.5×20% + 3.5×10% + 2.0×10% = 0.45 + 0.75 + 0.30 + 0.35 + 0.20 = 2.05 out of 5. The score describes financial and operational robustness over twelve to eighteen months. It is not a rating, a target price or an indication to buy or sell.

Red flags

  • Cash of $199.4 million at September 30, 2026 against $641.0 million of convertible notes, $200.0 million due in August 2029 and $441.0 million in December 2030.
  • Third-quarter operating cash use of $37.6 million, or $12.5 million a month, against $13.1 million a month over nine months.
  • Guidance cut twice in six months, from $165-175 million in May to $155-160 million in November.
  • GAAP gross margin down eight points to 33%, with consumables revenue down 2% while instrument revenue rose 16%.
  • Annualized Revio pull-through of about $204,000 against about $236,000: the cheaper chemistry is lowering revenue per installed system.
  • The chief executive (August 5, 2026) and the chief financial officer (November 3, 2026) both left their roles within three months, and the CEO now covers finance on an interim basis.
  • Overhang of 42.3 million shares in awards, 61.4 million issuable on the notes, 40.8 million available under the plans and a $100 million at-the-market program.
  • Covenants with SB Northstar, a SoftBank subsidiary, restrict additional debt and liens while it holds at least $180.0 million of the 2029 notes; goodwill of $317.8 million stands against negative stockholders’ equity of $61.4 million.
  • PGI payments of $5.0 million a year in 2027, 2028 and 2029, with revenue thresholds in 2027 that current guidance does not reach.

PACB Stock FAQ: PacBio Questions Answered

When is the next PacBio catalyst?

The next fixed item is the $5.0 million PGI installment due in the first quarter of 2027; the fourth-quarter and full-year 2026 results are expected in February 2027 and no date has been announced. PacBio reported third-quarter 2026 results on November 4, 2026: revenue of $40.6 million, a net loss of $0.12 a share and guidance of $155-160 million. Details.

How much revenue does PacBio make?

PacBio reported revenue of $40,564,000 for the quarter ended September 30, 2026, up 6% from $38,441,000 a year earlier, with consumables of $20.8 million, instruments of $13.2 million and service of $6.6 million. Nine-month revenue was $116.7 million and guidance is $155-160 million, against $160.0 million in 2025. Details.

How much cash does PacBio have, and how long will it last?

PacBio held $199.4 million of cash, equivalents and investments at September 30, 2026, against $279.5 million at December 31, 2025. Operations used $37.6 million in the third quarter, so the balance covers about five quarters at that rate, or about eight with the full $100 million at-the-market program; the company says its cash funds operations beyond the next twelve months. Details.

What was the 2024 debt exchange?

On November 7, 2024 PacBio agreed with SB Northstar LP, a SoftBank subsidiary, to exchange the remaining $459.0 million of its 1.50% notes due 2028 for $200.0 million of 1.50% notes due 2029, 20,451,570 shares and $50.0 million of cash; it closed on November 21, 2024 as a troubled debt restructuring, with a $154.4 million gain. A June 2023 exchange created the $441.0 million of 1.375% notes due 2030. Details.

When do PacBio’s convertible notes mature?

The $200.0 million of 1.50% notes mature on August 15, 2029 and the $441.0 million of 1.375% notes on December 15, 2030. They convert at about $4.89 and about $21.50 a share, far above the level at which the shares have traded; PacBio can settle in cash, shares or a combination, and its cash at September 30, 2026 was $199.4 million. Details.

Is PACB at risk of dilution?

Yes. PacBio had 312,926,730 shares at October 31, 2026, 42.3 million shares in equity awards, 61.4 million issuable on the notes, 40.8 million available under its equity plans and a $100 million at-the-market program; a further 20,451,570 shares were issued in the 2024 exchange. Details.

What does PacBio do?

Pacific Biosciences designs and sells long-read DNA sequencing systems built on single-molecule real-time sequencing: the Revio high-throughput instrument, the Vega benchtop instrument and the older Sequel systems, plus SMRT Cells, kits and service. Its HiFi reads typically reach median accuracies above Q30 (99.9%) at average lengths of 15-20 kilobases, according to the 2025 annual report, and the technology is used in human germline research, rare disease diagnostics, plant and animal science and oncology, all labeled for research use only. Details.

Is PacBio profitable?

No. PacBio reported an operating loss of $37.0 million and a net loss of $37.8 million, or $0.12 a share, in the quarter ended September 30, 2026, and a net loss of $90.9 million in nine months. Gross margin was 33% on a GAAP basis and non-GAAP operating expense ran at about $47.0 million a quarter, so the company needs substantially more revenue to reach operating break-even. Details.

Primary sources

Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent journalism and research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $PACB or any other security.

Figures are taken from filings with the U.S. Securities and Exchange Commission, company releases and peer-reviewed articles, and are stated with their reference dates. Data can change; readers should verify every figure against the primary source.

Small and mid-cap life science tools companies carry high execution and financing risk: products fail to win adoption, orders are cancelled or delayed, manufacturing costs rise, and companies that spend ahead of revenue raise equity at whatever price the market will bear. This company reported third-quarter 2026 revenue of $40.6 million against an operating loss of $37.0 million, held $199.4 million of cash and carries $641.0 million of convertible notes maturing in 2029 and 2030. Every reader is responsible for their own decisions and should consult a licensed financial adviser where appropriate.

Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.